Loading clinical trials...
Loading clinical trials...
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Conditions
Interventions
BGB-3245
Panitumumab
Locations
5
United States
City of Hope Comprehensive Cancer Center - Duarte
Duarte, California, United States
Duke Cancer Institute
Durham, North Carolina, United States
USOR - Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia, United States
Westmead Hospital
Westmead, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Start Date
April 18, 2024
Primary Completion Date
March 10, 2025
Completion Date
March 10, 2025
Last Updated
April 20, 2025
NCT07446322
NCT07541924
NCT04693377
NCT07529301
NCT07416552
NCT07523919
Lead Sponsor
MapKure, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions